Breathe Well Live Well
|
A Competitive Analysis of the Global Asthma and COPD Therapeutics Market …
PR Newswire (press release) oBenralizumab, a monoclonal antibody jointly being developed by MedImmune and AstraZeneca in Phase 3 trials. Benralizumab is bound to the interleukin-5 receptor (IL-5R?) and is being evaluated to help asthma control and reduce the onset of asthmatic … |
View full post on asthma – Google News
Effect of Common Comparators in Indirect Comparison Analysis of the Effectiveness of Different Inhaled Corticosteroids in the Treatment of Asthma.
PLoS One. 2015;10(3):e0120836
Authors: Kunitomi T, Hashiguchi M, Mochizuki M
Abstract
PURPOSE: Indirect comparison (IC) and direct comparison (DC) of four inhaled corticosteroid (CS) treatments for asthma were conducted, and the factors that may influence the results of IC were investigated. Among those factors, we focused on the effect of common comparator selection in the treatment of asthma, where little control group bias or placebo effect is expected.
METHOD: IC and DC were conducted using the change from baseline in forced expiratory volume in 1 s (FEV1(L)) as an outcome parameter. Differences between inhaled CS were evaluated to compare the results of IC and DC. As a common comparator for IC, placebo (PLB) or mometasone (MOM) was selected. Whether the results of IC are affected by the selection of a common comparator and whether the results of IC and DC are consistent were examined.
RESULTS: 23 articles were identified by a literature search. Our results showed that ICs yielded results similar to DCs in the change from baseline of FEV1(L). No statistically significant difference was observed in inconsistency analysis between ICs and DCs. It was clinically and statistically confirmed that ICs with PLB and those with MOM did not differ in terms of the results of FEV1(L) analysis in this dataset.
CONCLUSION: This study demonstrated that ICs among inhaled CS can deliver results consistent with those of DCs when using the change from baseline in FEV1(L) as an outcome parameter in asthma patients. It was also shown that using an active comparator has similar results if there is no effect of control group bias. It should be emphasized that the investigation of control group bias is a key factor in conducting relevant ICs so that an appropriate common comparator can be selected.
PMID: 25793900 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
COMMENTARY: Studying RGV asthma rates — Detailed A&M analysis of air …
Monitor Throughout the past two decades, asthma cases have steadily increased as a major pediatric health concern across the United States and in Texas. This is especially true in the Rio Grande Valley, which has the highest asthma-related hospitalization … |
View full post on asthma – Google News
|
MESA Analysis Uncovers Link Between Persistent Asthma and Cardiovascular …
Medscape CHICAGO, IL — An analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) suggests there may be an association between persistent asthma and the risk of cardiovascular disease. In a new study presented this week at the American Heart Association … |
View full post on asthma – Google News
Daily News & Analysis |
Asthma patients beware, Diwali is here
Daily News & Analysis Mithila Sawai (35), a human resource executive staying in Wadala has left the city to spend the weekend with her family in Himachal Pradesh. For asthmatic, Sawai, this is the only way she can escape from Diwali pollution. City-based chest physicians … |
View full post on asthma – Google News
|
Research and Markets: GSK's Flovent (Asthma) – Forecast and Market Analysis …
Business Wire (press release) Originally approved by the Food and Drug Administration (FDA) in 1996, GSK's Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in … Research and Markets: GSK's Bosatria (Mepolizumab) Asthma Treatment … |
View full post on asthma – Google News
|
PharmaPoint: Asthma – Japan Drug Forecast and Market Analysis to 2023
MarketWatch Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with … |
View full post on asthma – Google News
|
PharmaPoint: Asthma – US Drug Forecast and Market Analysis to 2023
MarketWatch Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with … |
View full post on asthma – Google News
|
PharmaPoint: Asthma – 5EU Drug Forecast and Market Analysis to 2023
MarketWatch Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with … |
View full post on asthma – Google News
|
Lebrikizumab Asthma Market Analysis and Forecast to 2023
WhaTech Researcher has released its new PharmaPoint Drug Evaluation report, “Lebrikizumab (Asthma) – Forecast and Market Analysis to 2023?. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious … |
View full post on asthma – Google News